Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT01757431 ·Status: COMPLETED ·Phase: PHASE2

Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China

NCT05876351 ·Status: COMPLETED ·Phase: PHASE3

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT02949128 ·Status: COMPLETED ·Phase: PHASE3

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

NCT07308574 ·Status: RECRUITING ·Phase: PHASE4

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

NCT05805202 ·Status: RECRUITING ·Phase: NA

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

NCT05726916 ·Status: RECRUITING ·Phase: PHASE3

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT03131219 ·Status: COMPLETED ·Phase: PHASE3

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

NCT00844545 ·Status: COMPLETED ·Phase: PHASE2

To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

NCT01755429 ·Status: COMPLETED

A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea

NCT05405777 ·Status: COMPLETED

Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)

NCT04859608 ·Status: COMPLETED ·Phase: PHASE3

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

NCT00844844 ·Status: COMPLETED ·Phase: PHASE2

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS

NCT00844428 ·Status: COMPLETED ·Phase: PHASE2

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

NCT00122304 ·Status: COMPLETED ·Phase: PHASE3

Complement Inhibition in aHUS Dialysis Patients

NCT02464891 ·Status: TERMINATED ·Phase: PHASE2

A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

NCT03303313 ·Status: WITHDRAWN ·Phase: PHASE2

Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

NCT05684159 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

NCT05795140 ·Status: RECRUITING ·Phase: PHASE3

Observational Study of Elizaria® in aHUS Patients

NCT04749810 ·Status: COMPLETED

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04958265 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

NCT04320602 ·Status: COMPLETED ·Phase: PHASE4

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

NCT00122330 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

NCT03205995 ·Status: TERMINATED ·Phase: PHASE3

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT02605993 ·Status: COMPLETED ·Phase: PHASE2